GlobeNewswire by notified

Cresemba® sales in Asia Pacific region trigger sales milestone payment to Basilea from Pfizer

Share

Basel/Allschwil, Switzerland, June 17, 2022

Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today that the sales of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. (NYSE: PFE, “Pfizer”) in the Asia Pacific region, exceeded the threshold triggering the first sales milestone payment for this region of USD 1.25 million.

David Veitch, Basilea’s Chief Executive Officer, stated: “We are very pleased with the commercial progress of Cresemba, which has now triggered the first sales milestone payment from Pfizer for the Asia Pacific region. The continued growth in the established markets in the US and Europe and the increasing contributions from new regions, such as Asia Pacific, confirm that Cresemba is serving a high medical need around the world.”

The license agreement between Basilea and Pfizer for Cresemba covers Europe (excluding the Nordic countries) as well as countries in the Asia Pacific region and China. Under the agreement with Pfizer, Basilea is eligible for additional regulatory and sales milestone payments of up to around CHF 550 million, in addition to receiving mid-teen royalties on sales.

Cresemba is approved in 68 countries to date and is currently marketed in 57 countries, including the United States, most EU member states and additional countries inside and outside of Europe. In the twelve months between January and December 2021, total global in-market sales of Cresemba amounted to USD 324 million, a 28 percent growth year-on-year.1

About isavuconazole (Cresemba)

Isavuconazole is an intravenous (i.v.) and oral azole antifungal, commercialized under the trade name Cresemba. Basilea has entered into several license and distribution agreements for isavuconazole, covering the United States, Europe, China, Japan, Latin America, Asia-Pacific, the Middle East and North Africa region, Canada, Russia, Turkey and Israel. In the 27 European Union member states, as well as in Iceland, Liechtenstein, Norway and the U.K., isavuconazole is approved for the treatment of adult patients with invasive aspergillosis and for the treatment of adult patients with mucormycosis for whom amphotericin B is inappropriate.2 In China, the oral formulation is approved for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis. Isavuconazole is also approved in the United States and several additional countries in Europe and beyond.3 It has orphan drug designation in the U.S., Europe and Australia for its approved indications.

About invasive aspergillosis and invasive mucormycosis

Invasive aspergillosis and invasive mucormycosis are life-threatening mold infections that predominantly affect immunocompromised patients, such as patients with hematologic malignancies (blood cancer). Both infections are associated with high morbidity and mortality.

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with bacterial and fungal infections and cancer. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. We are conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have several preclinical assets in both anti-infectives and cancer in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations
Basilea Pharmaceutica International Ltd, Allschwil
Hegenheimermattweg 167b
4123 Allschwil
Switzerland
Phone +41 61 606 1102
E-mail media_relations@basilea.com
investor_relations@basilea.com

This press release can be downloaded from www.basilea.com.

References

  1. IQVIA, December 2021. In-market sales reported as moving annual total (MAT) in U.S. dollar.
  2. European Public Assessment Report (EPAR) Cresemba: http://www.ema.europa.eu [Accessed: June 16, 2022]
  3. The registration status and approved indications may vary from country to country.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Arcoma vinner viktig upphandling i Finland. (MAR)27.6.2022 13:00:00 CEST | Pressemelding

2022-06-27 PRESSRELEASE Arcoma vinner viktig upphandling i Finland. Arcoma AB har vunnit viktig upphandlingpå upp till 6Arcoma Precision i5-system till ”HUS Medical Imaging Center” i Finland.Tre av systemen kommer att installeras under 2022 och kontraktet har en option på ytterligare tre system för installation under 2023. Det totala ordervärdet är upp till cirka 7,5MSek, beroende på tillval och optioner. Upphandlingen är vunnen av Lifemed Medical Systems som är Arcomas distributör och samarbetspartner i Finland och slutkunden är ”HUS Medical Imaging Center” som är en del av Helsingfors universitetssjukhus. "Vi är mycket glada över denna möjlighet att leverera dessa system till HUS, tillsammans med vår partner Arcoma. Ergonomi, patientsäkerhet och bra bildkvalitet var nyckelfaktorerna i detta anbud och Precision i5 är en perfekt lösning för att möta dessa behov ”, säger Mikko Isoviita, Sales Manager Lifemed Medical Systems. "Det är mycket glädjande att vi genom Lifemed vunnit denna upp

Arcoma wins important procurement in Finland. (MAR)27.6.2022 13:00:00 CEST | Press release

2022-06-27 PRESSRELEASE Arcoma wins important procurement in Finland. Arcoma AB has won important procurement of up to 6 Arcoma Precision i5 systems to “HUS Medical Imaging Center” in Finland. Three of the systems will be installed in 2022 and the contract has an option for three more systems for installation in 2023. The total order value is up to approximately SEK 7.5 million, depending on options. The procurement was won by Lifemed Medical Systems, which is Arcoma's distributor and partner in Finland, and the end customer is the “HUS Medical Imaging Center”, which is part of Helsinki University Hospital. "We are very pleased for this opportunity to supply these systems to HUS, together with our long-term partner Arcoma. Ergonomics, patient safety and good image quality were they key factors in this tender and Precision i5 is a perfect solution to address these needs”, says Mikko Isoviita, Sales Manager Lifemed Medical Systems. "It is great that we through Lifemed have won this procu

Change in Aspo’s Group Executive Committee27.6.2022 10:20:00 CEST | Press release

Aspo Plc Stock exchange release June 27, 2022 at 11:20 a.m. Change in Aspo’s Group Executive Committee Heli Arantola, Managing Director of Aspo’s subsidiary Leipurin, has resigned to join another company. Arantola will leave the company in December at the latest, and the process of selecting her successor has begun. “I thank Heli for her excellent contribution to the modernization of Leipurin and transforming the company in the rapidly changing bakery and food industry. I wish her the best of luck in her future endeavors,” says Rolf Jansson, CEO of Aspo Group. Aspo Plc Rolf Jansson CEO Further information, please contact: Rolf Jansson, CEO, Aspo Plc, +358 400 600 264, rolf.jansson@aspo.com DISTRIBUTION: Nasdaq Helsinki Key media www.aspo.com Aspo creates value by owning and developing business operations sustainably and in the long term. Our companies aim to be market leaders in their sectors. They are responsible for their own operations, customer relationships and the development of

Cool Company Ltd. – Mandatory Notification Of Trade27.6.2022 10:17:48 CEST | Press release

EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 24 June 2022 acquired 7,035 shares in the Company at a price of NOK 89.307527 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,598,523 shares in the Company, equivalent to 38.99% of the Company’s shares. Please see attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment Primary insider notification form

Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme27.6.2022 08:45:00 CEST | Press release

Company Announcement No. 43/2022 Copenhagen, 27 June 2022 Transactions in connection with share buy-back programme On 19 May 2022, Scandinavian Tobacco Group A/S announced that the share buy-back programme that was initiated 9 March 2022 was increased to an aggregated value of up to DKK 1,000 million. The purpose of the programme is to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. Part of the buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Another part of the share buy-back programme is conducted as a directed buy-back from Chr. Augustinus Fabrikker Aktieselskab and C.W. Obel A/S as further described in company announcement no. 35/2022. The share buy-back programme will end no later than 28 February 2023. The